Karbicombi (Hydrochlorothiazide, Candesartan Cilexetil)

Hydrochlorothiazide acts on the distal convoluted tubule of the kidney to block Na⁺/Cl⁻ reabsorption, promoting diuresis and decreasing plasma volume. Candesartan cilexetil is converted to candesartan, which selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Together they reduce fluid overload and relax blood vessels, producing an additive antihypertensive effect.

The specific dose of Karbicombi is determined by the prescribing clinician based on the patient’s blood pressure, renal function, and overall clinical profile. Dosage adjustments are made according to therapeutic response and tolerability, and the medication should be taken exactly as directed by a qualified healthcare professional.

The safety of Karbicombi in pregnancy and lactation has not been fully established. Candesartan is generally contraindicated in the second and third trimesters because of potential fetal toxicity, and thiazide diuretics are used with caution. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatment options with their physician.

To request Karbicombi, visit the product page on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Compared with monotherapy using either a thiazide diuretic or an ARB alone, the Karbicomi fixed‑dose combination offers synergistic blood‑pressure reduction, potentially improving adherence by reducing pill burden. It may provide better control in patients who require both volume reduction and vascular relaxation, whereas single‑agent therapy might be insufficient for some individuals.

Karbicombi tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Karbicombi is taken orally, usually once daily in the morning, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew it, as this could affect the drug’s release profile.

The most serious adverse events to monitor include severe allergic reactions (anaphylaxis), significant electrolyte disturbances such as hyperkalemia or hyponatremia, acute kidney injury, and rare blood disorders like agranulocytosis. Patients should seek immediate medical attention if they experience symptoms such as swelling of the face or throat, persistent vomiting, muscle weakness, or unexplained bruising.

Karbicombi is contraindicated in patients with known hypersensitivity to either component, severe renal or hepatic impairment, and in pregnant women during the second and third trimesters. It should also be avoided in individuals taking potassium‑sparing diuretics or supplements without close monitoring, and in those with a history of angio‑edema related to ARB therapy.